Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Rosangela Marchelli is active.

Publication


Featured researches published by Rosangela Marchelli.


EFSA Journal | 2010

Scientific Opinion on Dietary Reference Values for carbohydrates and dietary fibre

Carlo Agostoni; Jean-Louis Bresson; S. Fairweather Tait; Albert Flynn; I. Golly; Hannu Korhonen; Pagona Lagiou; Martinus Løvik; Rosangela Marchelli; Ambroise Martin; Bevan Moseley; M. Neuhäuser Berthold; Hildegard Przyrembel; Seppo Salminen; Yolanda Sanz; S. Strain; Stephan Strobel; Inge Tetens; Daniel Tomé; H. van Loveren; H. Verhagen

This Opinion of the EFSA Panel on Dietetic Products, Nutrition, and Allergies (NDA) deals with the establishment of Dietary Reference Values for carbohydrates and dietary fibre. Nutritionally, two broad categories of carbohydrates can be differentiated: “glycaemic carbohydrates”, i.e. carbohydrates digested and absorbed in the human small intestine, and ‘dietary fibre’, non-digestible carbohydrates passing to the large intestine. In this Opinion, dietary fibre is defined as non-digestible carbohydrates plus lignin. The absolute dietary requirement for glycaemic carbohydrates is not precisely known but will depend on the amount of fat and protein ingested. The Panel proposes 45 to 60 E% as the reference Intake range for carbohydrates applicable to both adults and children older than one year of age. Although high frequency of intake of sugar-containing foods can increase the risk of dental caries, there are insufficient data to set an upper limit for (added) sugar intake. Based on the available evidence on bowel function, the Panel considers dietary fibre intakes of 25 g/day to be adequate for normal laxation in adults. A fibre intake of 2 g/MJ is considered adequate for normal laxation in children from the age of one year. Although there is some experimental evidence that a reduction of the dietary glycaemic index and glycaemic load may have favourable effects on some metabolic risk factors such as serum lipids, the evidence for a role in weight maintenance and prevention of diet-related diseases is inconclusive.


EFSA Journal | 2017

Safety of hydroxytyrosol as a novel food pursuant to Regulation (EC) No 258/97

Dominique Turck; Jean-Louis Bresson; Barbara Burlingame; Tara Dean; Susan J. Fairweather-Tait; Marina Heinonen; Karen Ildico Hirsch‐Ernst; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Monika Neuhäuser‐Berthold; Grażyna Nowicka; Kristina Pentieva; Yolanda Sanz; Alfonso Siani; Anders Sjödin; Martin Stern; Daniel Tomé; Marco Vinceti; Peter Willatts; Karl-Heinz Engel; Rosangela Marchelli; Annette Pöting; Morten Poulsen; Josef Schlatter; Emanuela Turla; Henk van Loveren

Abstract Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on hydroxytyrosol, which is chemically synthesised, as a novel food (NF) pursuant to Regulation (EC) No 258/97. The information provided on the composition, specifications, batch‐to‐batch variability, stability and production process of the NF is sufficient and does not raise concerns about the safety of the NF. The applicant intends to add hydroxytyrosol to fish and vegetable oils up to 215 mg/kg and to margarines up to 175 mg/kg. The target group is the general population which excludes children under 36 months of age, pregnant women and breastfeeding women. Considering the no observed adverse effect level (NOAEL) of 50 mg/kg body weight per day from a subchronic oral toxicity study with the NF and the maximum anticipated daily intake for the NF, the margin of exposure (MoE) would result in 100 for children (3–9 years of age) and at least 200 for adolescents, adults (excluding pregnant and breastfeeding women) and elderly. Taking into account that the anticipated daily intake of the NF would be in the range of or even less than the exposure of hydroxytyrosol from the consumption of olive oils and olives, which has not been associated with adverse effects, and considering the similar kinetics of hydroxytyrosol in rats and humans, the Panel considers that the MoE for the NF at the intended uses and use levels is sufficient for the target population. The Panel concludes that the novel food, hydroxytyrosol, is safe under the proposed uses and use levels.


EFSA Journal | 2017

Safety of alginate-konjac-xanthan polysaccharide complex (PGX) as a novel food pursuant to Regulation (EC) No 258/97

Dominique Turck; Jean-Louis Bresson; Barbara Burlingame; Tara Dean; Susan J. Fairweather-Tait; Marina Heinonen; Karen Ildico Hirsch‐Ernst; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Monika Neuhäuser‐Berthold; Grażyna Nowicka; Kristina Pentieva; Yolanda Sanz; Alfonso Siani; Anders Sjödin; Martin Stern; Daniel Tomé; Marco Vinceti; Peter Willatts; Karl-Heinz Engel; Rosangela Marchelli; Annette Pöting; Morten Poulsen; Josef Schlatter; Emanuela Turla; Henk van Loveren

Abstract Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a scientific opinion on alginate‐konjac‐xanthan polysaccharide complex (PGX) as a novel food (NF) submitted pursuant to Regulation (EC) No 258/97. The NF is an off‐white granular powder composed of three non‐starch polysaccharides: konjac glucomannan, xanthan gum and sodium alginate. The information provided on the composition, the specifications, the batch‐to‐batch variability and the stability of the NF is sufficient and does not raise safety concerns. The production process is sufficiently described and does not raise concerns about the safety of the NF. The applicant intends to add the NF to a variety of foods as well as to market the NF in capsules. The recommended maximum daily intake of the NF from fortified foods and food supplements is 15 g. The target population proposed by the applicant is adults from 18 to 64 years of age. Considering the no observed adverse effect level of 1.8 g/kg body weight (bw) per day in a subchronic toxicity study with PGX and the highest mean and 95th percentile anticipated daily intake of NF from fortified foods, the margin of exposure (MoE) is 12 and 6, respectively, whereas the MoE for the NF from food supplements is 9. The Panel concludes that the safety of the novel food, PGX, for the intended uses and use levels as proposed by the applicant, has not been established.


EFSA Journal | 2017

Safety of cranberry extract powder as a novel food ingredient pursuant to Regulation (EC) No 258/97

Dominique Turck; Jean-Louis Bresson; Barbara Burlingame; Tara Dean; Susan J. Fairweather-Tait; Marina Heinonen; Karen Ildico Hirsch‐Ernst; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Monika Neuhäuser‐Berthold; Grażyna Nowicka; Kristina Pentieva; Yolanda Sanz; Alfonso Siani; Anders Sjödin; Martin Stern; Daniel Tomé; Marco Vinceti; Peter Willatts; Karl-Heinz Engel; Rosangela Marchelli; Annette Pöting; Morten Poulsen; Josef Schlatter; Wolfgang Gelbmann; Henk van Loveren

Abstract Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on ‘cranberry extract powder’ as a novel food (NF) submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council. The NF contains about 55–60% proanthocyanidins (PACs). The Panel considers that the information provided on the composition, the specifications, batch‐to‐batch variability and stability of the NF is sufficient and does not raise safety concerns. Cranberry extract powder is produced from cranberry juice concentrate through an ethanolic extraction using an adsorptive resin column to retain the phenolic components. The Panel considers that the production process is sufficiently described and does not raise concerns about the safety of the novel food. The NF is intended to be added to beverages and yogurts to provide 80 mg PACs per serving. The target population is the adult general population. The mean and 95th percentile estimates for the all‐user intakes from all proposed food‐uses are 68 and 192 mg/day, respectively, for female adults, and 74 mg/day and 219 mg/day, respectively, for male adults. Taking into account the composition of the novel food and the intended use levels, the Panel considers that the consumption of the NF is not nutritionally disadvantageous. While no animal toxicological studies have been conducted on the NF, a number of human clinical studies have been conducted with cranberry products. Considering the composition, manufacturing process, intake, history of consumption of the source and human data, the Panel considers that the data provided do not give reasons for safety concerns. The Panel concludes that the cranberry extract powder is safe as a food ingredient at the proposed uses and use levels.


EFSA Journal | 2017

Safety of betaine as a novel food pursuant to Regulation (EC) No 258/97

Dominique Turck; Jean-Louis Bresson; Barbara Burlingame; Tara Dean; Susan J. Fairweather-Tait; Marina Heinonen; Karen Ildico Hirsch‐Ernst; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Monika Neuhäuser‐Berthold; Grażyna Nowicka; Kristina Pentieva; Yolanda Sanz; Alfonso Siani; Anders Sjödin; Martin Stern; Daniel Tomé; Marco Vinceti; Peter Willatts; Karl-Heinz Engel; Rosangela Marchelli; Annette Pöting; Morten Poulsen; Josef Schlatter; Emanuela Turla; Henk van Loveren

Abstract Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on betaine as a novel food (NF) pursuant to Regulation (EC) No 258/97. The information provided on the composition, the specifications, the batch‐to‐batch variability, stability and production process of the NF is sufficient and does not raise concerns about the safety of the NF. The NF is proposed to be used in foods intended to meet additional requirements for intense muscular effort with a maximum intake of 2.5 g/day of betaine for sports people above 10 years of age. Based on the lowest BMDL05, which was derived from a chronic toxicity study in rats in which a dose‐related increase in platelet counts was observed, and the anticipated daily intake of the NF in the target population, the Margins of Exposure are 3.6 and 5, which are generally regarded as not sufficient. However, the total exposure to betaine from the diet (about 830 mg/day) is not known to be associated with adverse effects. Moreover, no adverse effects on platelet counts were noted in human intervention studies with exposure levels of 4 g/day of betaine for up to 6 months. A significant increase in total and low‐density lipoprotein (LDL)‐cholesterol concentrations was noted at intakes of 4 g/day of betaine in overweight subjects with metabolic syndrome but not in healthy subjects, nor at intakes of 3 g/day. Thus, considering 4 g/day of betaine as a reference point and applying an uncertainty factor of 10 to account for interindividual variability, an amount of 400 mg/day of betaine (i.e. 6 mg/kg body weight (bw) per day for adults) in addition to the background exposure is considered as safe. The Panel considers that the NF is safe to be used at maximum intake of 6 mg/kg bw per day in the target population.


EFSA Journal | 2018

Safety of Allanblackia seed oil for extended uses in vegetable oils and milk and in yellow fat and cream‐based spreads up to 30% (w/w)

Dominique Turck; Jean-Louis Bresson; Barbara Burlingame; Tara Dean; Susan Fairweather‐Tait; Marina Heinonen; Karen Ildico Hirsch‐Ernst; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Monika Neuhäuser‐Berthold; Grażyna Nowicka; Kristina Pentieva; Yolanda Sanz; Alfonso Siani; Anders Sjödin; Martin Stern; Daniel Tomé; Marco Vinceti; Peter Willatts; Karl-Heinz Engel; Rosangela Marchelli; Annette Pöting; Morten Poulsen; Josef Schlatter; Wolfgang Gelbmann; Henk van Loveren

Abstract In 2007, the EFSA NDA Panel concluded that Allanblackia seed oil obtained from the seeds of Allanblackia trees is safe for human consumption under the proposed conditions of use. Due to its high contents of stearic‐oleic‐stearic and stearic‐oleic‐oleic triglycerides, which made the oil suitable as a ‘hardstock’ component, the applicant applied for its use as a novel food (NF) ingredient in yellow fat and cream‐based spreads at a level of 20% (w/w). In this application, the applicant seeks (1) to increase the authorised maximum use level (i.e. 20% w/w) in yellow fat spreads and cream‐based spreads to 30% (w/w) and (2) the use of this NF in mixes of vegetable oils and milk up to a maximum use level of 30% (w/w). (3) The applicant proposes also some changes in the specifications of the NF, although he noted that the oil is collected, extracted and refined using the same processes that are currently used for other edible vegetable oils and which have been evaluated in the original application assed by EFSA in 2007. According to the information provided by the applicant, the production process and the composition of the NF do not change. The Panel notes that the revised specification limits on trans‐fatty acid (TFA), unsaponifiable matter, peroxide value are similar to those for other edible oils and fats. The applicant also indicated that he had performed an updated comprehensive literature search using several different databases, but no preclinical studies or human studies on Allanblackia seed oil were identified which have not been provided for the previous EFSA assessment in 2007. The Panel notes that the proposed extended uses would increase the potential intake of the NF, which is considered not to be nutritionally disadvantageous. The Panel concludes that Allanblackia seed oil is safe at the extended uses and use level.


EFSA Journal | 2018

Safety of Whey basic protein isolates as a novel food pursuant to Regulation (EU) 2015/2283

Dominique Turck; Jean-Louis Bresson; Barbara Burlingame; Tara Dean; Susan Fairweather‐Tait; Marina Heinonen; Karen Ildico Hirsch‐Ernst; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Monika Neuhäuser‐Berthold; Grażyna Nowicka; Kristina Pentieva; Yolanda Sanz; Alfonso Siani; Anders Sjödin; Martin Stern; Daniel Tomé; Marco Vinceti; Peter Willatts; Karl-Heinz Engel; Rosangela Marchelli; Annette Pöting; Morten Poulsen; Josef Schlatter; Mathias Amundsen; Henk van Loveren

Abstract Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on whey basic protein isolate as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is obtained by ion exchange chromatography of skimmed cows milk. The applicant intends to market the NF in infant and follow‐on formulae and meal replacement beverages, dietary foods for special medical purposes and as food supplements. The highest estimated intake of the NF based on the proposed uses and use levels would be 24.8 mg/kg body weight (bw) per day in infants and 27.8 in toddlers. The information provided on composition, specifications, production process and stability of the NF do not raise safety concerns. Taking into account the composition of the NF and the intended use levels, the Panel considers that the consumption of the NF is not nutritionally disadvantageous. The Panel considers that there is no concern with respect to genotoxicity. The no observed adverse effect level (NOAEL) of a subchronic 13‐week rat study was 2000 mg/kg bw per day. Considering the source, the production process and nature of the NF, the Panel considers the margin of exposure (MOE) of 154 to be sufficient for the adult population (on a high‐estimated intake of 13 mg/kg bw). For infants and toddlers, the MOE would be at least 81 and 72, respectively. Taking into account the composition of the NF, its source, the history of consumption of the main components of the NF, the production process and that the NOAEL in a subchronic rat study was the highest dose tested the Panel considers that also the MOE for infants and toddlers are sufficient. The Panel concludes that the novel food ingredient, whey basic protein isolate, is safe under the proposed uses and use levels.


EFSA Journal | 2018

Safety of shrimp peptide concentrate as a novel food pursuant to Regulation (EU) 2015/2283

Dominique Turck; Jean-Louis Bresson; Barbara Burlingame; Tara Dean; Susan Fairweather‐Tait; Marina Heinonen; Karen Ildico Hirsch‐Ernst; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Monika Neuhäuser‐Berthold; Grażyna Nowicka; Kristina Pentieva; Yolanda Sanz; Alfonso Siani; Anders Sjödin; Martin Stern; Daniel Tomé; Marco Vinceti; Peter Willatts; Karl-Heinz Engel; Rosangela Marchelli; Annette Pöting; Morten Poulsen; Josef Schlatter; Leonard Matijević; Henk van Loveren

Abstract Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on shrimp peptide concentrate as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is a peptide mixture obtained by an enzymatic proteolysis from northern shrimp (Pandalus borealis) shells and heads. The information provided on the composition, specifications, batch‐to‐batch variability, stability and production process of the NF is sufficient and does not raise safety concerns. The intention of the applicant is to use this NF as an ingredient in food supplements and to market it to adult consumers at a maximum proposed level of intake of 1,200 mg/day (corresponding to 17 mg/kg body weight (bw) per day for a 70 kg person). There are no concerns with regard to genotoxicity. The available human data do not raise safety concerns. Considering the no observed adverse effect level (NOAEL) of 2,000 mg/kg bw per day from a 90‐day repeated‐dose oral toxicity study, the maximum proposed level of intake and the nature of the NF, the Panel concludes that the margin of exposure (of 117) is sufficient. The Panel concludes that the NF, shrimp peptide concentrate, is safe to be used as a food supplement at the proposed maximum dose of 1,200 mg/day. The target population is adults. The Panel considered that the conclusion on the safety of the NF could not have been reached without the data from the unpublished study report on repeated‐dose 90‐day oral toxicity and from the unpublished study reports on two human studies.


EFSA Journal | 2018

Safety of egg membrane hydrolysate as a novel food pursuant to Regulation (EU) 2015/2283

Dominique Turck; Jean-Louis Bresson; Barbara Burlingame; Tara Dean; Susan Fairweather‐Tait; Marina Heinonen; Karen Ildico Hirsch‐Ernst; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Monika Neuhäuser‐Berthold; Grażyna Nowicka; Kristina Pentieva; Yolanda Sanz; Alfonso Siani; Anders Sjödin; Martin Stern; Daniel Tomé; Marco Vinceti; Peter Willatts; Karl-Heinz Engel; Rosangela Marchelli; Annette Pöting; Josef Schlatter; Reinhard Ackerl; Henk van Loveren

Abstract Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver a scientific opinion on egg membrane hydrolysate as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is a water‐soluble hydrolysate of egg membrane, produced by alkaline treatment of the thin layer lining the shells of chicken eggs. The main constituents of the NF are elastin, collagen and glycosaminoglycans. The information provided on the production process, batch‐to‐batch variability, composition and specifications of the NF is sufficient and does not raise safety concerns. The NF is proposed to be used as a food supplement for adults, at a maximum daily amount of 450 mg. The consumption of the NF is not nutritionally disadvantageous. One human study, which was not designed for safety but included a number of endpoints pertaining to safety, did not raise safety concerns. The Panel considers that taking into account the information provided and considering the nature, the source and the production process of the NF, there are no safety concerns for the NF at the proposed conditions of use. The Panel concludes that the NF, egg membrane hydrolysate, is safe as a food supplement at a dose of 450 mg/day. The target population for the NF is the general adult population.


EFSA Journal | 2017

Statement on the safety of EstroG‐100™ as a novel food pursuant to Regulation (EC) No 258/97

Dominique Turck; Jean-Louis Bresson; Barbara Burlingame; Tara Dean; Susan J. Fairweather-Tait; Marina Heinonen; Karen Ildico Hirsch‐Ernst; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Monika Neuhäuser‐Berthold; Grażyna Nowicka; Kristina Pentieva; Yolanda Sanz; Alfonso Siani; Anders Sjödin; Martin Stern; Daniel Tomé; Marco Vinceti; Peter Willatts; Karl-Heinz Engel; Rosangela Marchelli; Annette Pöting; Morten Poulsen; Josef Schlatter; Emanuela Turla; Henk van Loveren

Abstract Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to update its scientific opinion on the safety of EstroG‐100™ as a novel food (NF) in the light of additional information submitted by the applicant. In its previous scientific opinion of 2016, the Panel concluded that EstroG‐100™, which is a hot‐water extract of a mixture of three herbal roots, is safe for the use in food supplements at the maximum intake level of 175 mg/day in post‐menopausal women, which is lower than the maximum intake level proposed by the applicant (514 mg/day). The Panel reached its conclusions based on the effects of EstroG‐100™ on liver and haematology as observed in several oral toxicity studies, the lack of information on liver and haematological parameters in human studies and the absence of chronic toxicity data. In view of the Panels conclusion on the safety of EstroG‐100™, the applicant has now provided additional information on haematological and liver parameters for the human intervention study with EstroG‐100™ and historical control data related to the subchronic 90‐day oral toxicity study with EstroG‐100™. After assessing the additional information provided by the applicant, the Panel considers that the conclusion of the scientific opinion on the safety of EstroG‐100™ does not need to be revised, and thus, the Panel reconfirms that the NF is safe for the use in food supplements at the maximum intake level of 175 mg/day in post‐menopausal women.

Collaboration


Dive into the Rosangela Marchelli's collaboration.

Top Co-Authors

Avatar

Yolanda Sanz

Spanish National Research Council

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Androniki Naska

National and Kapodistrian University of Athens

View shared research outputs
Top Co-Authors

Avatar

Anders Sjödin

University of Copenhagen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Martin Stern

University of Tübingen

View shared research outputs
Top Co-Authors

Avatar

Annette Pöting

Federal Institute for Risk Assessment

View shared research outputs
Top Co-Authors

Avatar

Josef Schlatter

European Food Safety Authority

View shared research outputs
Top Co-Authors

Avatar

Morten Poulsen

Technical University of Denmark

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge